---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-007924"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:48:17.468625+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma Q3 2023 revenues surge to $5.96M on Nora Pharma acquisition; net loss narrows to $0.04/sh

## Summary
- Gross revenues $5,957,668 for Q3 2023, up from $132,808 a year earlier, driven by Nora Pharma Inc. acquisition.
- Net loss from operations narrowed to $651,482 ($0.04 per share) from $1,457,019 ($0.12 per share) in Q3 2022.
- Sequential revenue growth: 7.1% from Q2 2023 ($5,560,865) and 21.7% from Q1 2023 ($4,894,053).
- CEO Steve Slilaty stated focus on cost cutting and reaching profitability as key goals going forward.

## SEC filing metadata
- accession: 0001683168-23-007924
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316823007924/0001683168-23-007924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316823007924/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-007924
- JSON: https://secwatch.observer/filing/0001683168-23-007924.json
- Plain text: https://secwatch.observer/filing/0001683168-23-007924.txt

## Key facts
- Earnings Releases
  Sunshine Biopharma Inc. reported the quarter ended September 30, 2023 results: revenue $5,957,668, net income net loss of $651,482 ($0.04 per share).
  - Period: the quarter ended September 30, 2023
  - Revenue: $5,957,668
  - Net income: net loss of $651,482 ($0.04 per share)
  - Result: reported results
  source text: Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly report for the 2023 third quarter. The Company reported gross revenues of $5,957,668 for the quarter ended September 30, 2023, an increase of $5,824,860 over the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316823007924/0001683168-23-007924-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.